Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To analyze the efficacy and safety of nalfurafine hydrochloride in treating chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients.
This study adopted a multicenter, single-arm, self-controlled before-after design. Patients with CKD-aP undergoing HD at 13 blood purification centers, including The First Affiliated Hospital of Zhengzhou University, from December 2024 to May 2025 were enrolled. All subjects received nalfurafine hydrochloride orally disintegrating tablets (2.5 μg qd) for 14 days, followed by a 14-day follow-up without the medication. The severity of pruritus was assessed daily using the visual analogue scale (VAS), and the treatment efficacy was also evaluated by the VAS scores. Adverse events were closely monitored. Paired t-tests were performed to compare the daily VAS scores during treatment with baseline, and Kaplan–Meier analysis was used to assess the time to onset of efficacy. Furthermore, univariate and multivariate ordered logistic regression were used to explore factors associated with therapeutic efficacy.
A total of 61 HD patients were enrolled in this study, including 38 males (62.30%), aged 62.07±12.29 years, with a dialysis vintage of 64.18±40.31 months. At baseline, 14 patients (22.95%) had moderate, 22 patients (36.07%) had severe, and 25 patients (40.98%) had extremely severe pruritus. During treatment, the VAS scores decreased most significantly in the first week (64.90±14.43mm vs 83.72±13.98mm, P <0.001). Although slight fluctuations occurred in the second week, VAS scores remained significantly lower than baseline (55.88±16.64 vs 83.72±13.98mm, P<0.001). The overall response rate reached 68.33% after 14 days of treatment, and the median time to onset of effect was 4 days. The incidence of adverse events was 9.84%. Multivariate ordered logistic regression analysis indicated that the frequency of hemodiafiltration was an independent factor associated with the antipruritic efficacy of nalfurafine hydrochloride(OR=0.24, 95%CI 0.06~0.90, P=0.035).
Nalfurafine hydrochloride effectively relieves pruritus symptoms in HD patients and has a good safety profile.
